AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Chemotherapy Induced Anemia - Pipeline Insight, 2019 - ResearchAndMarkets.com

March 13, 2019

DUBLIN--(BUSINESS WIRE)--Mar 13, 2019--The “Chemotherapy Induced Anemia - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Chemotherapy Induced Anemia - Pipeline Insight, 2019 offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Chemotherapy Induced Anemia development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

  • The report provides a snapshot of the pipeline development for the Chemotherapy Induced Anemia
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Chemotherapy Induced Anemia
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Chemotherapy Induced Anemia
  • The report also covers the dormant and discontinued pipeline projects related to Chemotherapy Induced Anemia

Companies Featured

  • 3SBio Inc.
  • Chong Kun Dang Pharmaceutical Corp.
  • Dr. Reddy’s Laboratories Ltd.
  • Galenica Ltd.
  • Novartis
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • PharmaEssentia Corp.
  • PhytoHealth Corp.
  • Pieris Pharmaceuticals Inc.

Topics Covered

1. Report Introduction

2. Chemotherapy Induced Anemia Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Chemotherapy Induced Anemia

4. Comparative Analysis

5. Products in Clinical Stage

5.1 Drug Name : Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

6.1 Drug Name : Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

8. Inactive Products

8.1 Drug Name : Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/f63bd5/chemotherapy?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190313005378/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Hematological Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 03/13/2019 07:31 AM/DISC: 03/13/2019 07:31 AM

http://www.businesswire.com/news/home/20190313005378/en